rss
05-11-2017, 10:24 PM
Boston Sci’s Long Lasting Resonate ICDs and CRT-Ds Get FDA Approval
http://www.medgadget.com/wp-content/uploads/2017/05/Resonate-CRT-D.png
Boston Scientific won FDA approval to introduce its Resonate line of implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D). The same products were approved in Europe via a CE Mark earlier this year.
Some of the **table features of the Resonate devices include*multi-electrode pacing and integration with*the company’s*HeartLogic Heart Failure Diag**stic Service, essentially an algorithm that seems to do a good job predicting heart failure events (http://news.bostonscientific.com/2016-11-16-Boston-Scientific-An**unces-Positive-Results-Of-HeartLogic-Heart-Failure-Diag**stic-Service).
New battery tech**logy allows Boston Scientific to claim an overall working lifetime for Resonate ICD devices at twice that of Medtronic’s*Evera XT VR.
More from Boston Scientific’s an**uncement:
The company has initiated a ****** of clinical trials, the SMART Registry, SMART CRT Study and SMART MSP, to demonstrate improved response to CRT therapy with SmartCRT tech**logy, which helps physicians optimize where, when, and how to pace the lower chambers of the heart.
“These trials will add to the body of evidence showing CRT therapy can be tailored to individual patient characteristics at the time of implant, while adjusting device programming solutions over the life of the device without fear of adversely draining the device battery and causing unnecessary replacement procedures,” said Dr. Michael Gold, principal investigator of the SMART CRT study and the Michael E. Assey professor of medicine at The Medical University of South Carolina, Charleston.
Product page: RESONATE… (http://www.bostonscientific.com/en-EU/products/crt-d/resonate-crtd.html)
Via: Boston Scientific… (http://news.bostonscientific.com/2017-05-09-Boston-Scientific-Receives-U-S-FDA-Approval-For-Resonate-TM-Family-Of-High-Voltage-Devices)
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=Hh5vtP0_9p4:SjP6IS3Jous:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=Hh5vtP0_9p4:SjP6IS3Jous:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=Hh5vtP0_9p4:SjP6IS3Jous:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=Hh5vtP0_9p4:SjP6IS3Jous:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/Hh5vtP0_9p4
http://www.medgadget.com/wp-content/uploads/2017/05/Resonate-CRT-D.png
Boston Scientific won FDA approval to introduce its Resonate line of implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D). The same products were approved in Europe via a CE Mark earlier this year.
Some of the **table features of the Resonate devices include*multi-electrode pacing and integration with*the company’s*HeartLogic Heart Failure Diag**stic Service, essentially an algorithm that seems to do a good job predicting heart failure events (http://news.bostonscientific.com/2016-11-16-Boston-Scientific-An**unces-Positive-Results-Of-HeartLogic-Heart-Failure-Diag**stic-Service).
New battery tech**logy allows Boston Scientific to claim an overall working lifetime for Resonate ICD devices at twice that of Medtronic’s*Evera XT VR.
More from Boston Scientific’s an**uncement:
The company has initiated a ****** of clinical trials, the SMART Registry, SMART CRT Study and SMART MSP, to demonstrate improved response to CRT therapy with SmartCRT tech**logy, which helps physicians optimize where, when, and how to pace the lower chambers of the heart.
“These trials will add to the body of evidence showing CRT therapy can be tailored to individual patient characteristics at the time of implant, while adjusting device programming solutions over the life of the device without fear of adversely draining the device battery and causing unnecessary replacement procedures,” said Dr. Michael Gold, principal investigator of the SMART CRT study and the Michael E. Assey professor of medicine at The Medical University of South Carolina, Charleston.
Product page: RESONATE… (http://www.bostonscientific.com/en-EU/products/crt-d/resonate-crtd.html)
Via: Boston Scientific… (http://news.bostonscientific.com/2017-05-09-Boston-Scientific-Receives-U-S-FDA-Approval-For-Resonate-TM-Family-Of-High-Voltage-Devices)
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=Hh5vtP0_9p4:SjP6IS3Jous:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=Hh5vtP0_9p4:SjP6IS3Jous:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=Hh5vtP0_9p4:SjP6IS3Jous:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=Hh5vtP0_9p4:SjP6IS3Jous:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/Hh5vtP0_9p4